Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer.
10.4046/trd.2005.58.5.465
- Author:
Hyun Mo KANG
1
;
Jeong Eun LEE
;
Pil Soon JANG
;
Yun Sun LEE
;
Sun Jung KWON
;
Jin Young AN
;
Sung Soo JUNG
;
Ju Ock KIM
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Cancer Research Institute, Chungnam National University, Daejeon, Korea. sykim@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Docetaxel;
Non-small cell lung cancer;
Second-line chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Disease-Free Survival;
Drug Therapy;
Humans;
Lung Neoplasms;
Neutropenia;
Premedication
- From:Tuberculosis and Respiratory Diseases
2005;58(5):465-472
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second-line chemotherapy, for which Docetaxel (Taxotere(R)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum- based chemotherapy. METHODS: Thirty one patients with non-small-cell lung cancer, who had failed first-line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/m2 or 100 mg/m2, with routine premedication every three weeks. RESULTS: Fourteen patients (45.2%) had a partial response. The median survival and progression-free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > or = 60 years: 6.6 months, p = 0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment-related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. CONCLUSION: Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small- cell lung cancer who failed first-line platinum-based chemotherapy.
